![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » PTAB Grants Inter Partes Review for Narcan Spray Patent
PTAB Grants Inter Partes Review for Narcan Spray Patent
![PatentsTabLabel.gif](https://www.fdanews.com/ext/resources/test/Drug-Images4/PatentsTabLabel.gif?t=1579739301&width=430)
September 6, 2019
The U.S. Patent Trial and Appeal Board (PTAB) has decided to conduct an inter partes review of Opiant Pharmaceutical’s patent covering its opioid-overdose treatment Narcan (naloxone).
The patent’s challenger, Nalox-1 Pharmaceuticals, claims that Opiant’s patent (9,211,253) for the nasal spray version of the drug is invalid because it is common knowledge available to anyone experienced in solutions-based drug development. PTAB agreed that this argument would likely prevail.
The board threw out several parallel challenges filed by Nalox-1 to avoid redundancy. PTAB asked the parties to rank the challenges in order of importance and they chose this Nalox-1 claim for review.
Upcoming Events
-
21Oct